Novel pharmacological approaches have shown promise in targeting key pathways influencing the development and exacerbation of NEC, for example, as demonstrated by oligosaccharide TLR4 inhibitors (Neal et al. 2013; Wipf et al. 2015). This evidence concerns the gene TLR4 and necrotizing enterocolitis.